The risk of infection with new oral anticoagulants: A meta-analysis

International Journal of Cardiology

Volumn 172, Issue 1, 2014, Pages 267-268

  Caldeira, Daniel ^a,b   Costa, João ^a,b   Pinto, Fausto J ^b   Ferreira, Joaquim J ^a,b  

^a INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^b INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

Apixaban; Dabigatran; Infection; Meta analysis; Rivaroxaban; Urinary tract infection

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; DAREXABAN; EDOXABAN; RIVAROXABAN; MORPHOLINE DERIVATIVE; THIOPHENE DERIVATIVE;

ANTICOAGULANT THERAPY; COMPARATIVE STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DRUG EFFICACY; HUMAN; INFECTION RISK; INTERPRETATION BIAS; LETTER; META ANALYSIS (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; URINARY TRACT INFECTION; VALIDATION STUDY; MALE; SEPSIS; STROKE; URINARY TRACT INFECTIONS;

ANTICOAGULANTS; HUMANS; MALE; MORPHOLINES; SEPSIS; STROKE; THIOPHENES; URINARY TRACT INFECTIONS;

EID: 84894088687     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.12.248     Document Type: Article

References (15)

1. C. Stöllberger, and J. Finsterer Stroke and urosepsis after discontinuation of rivaroxaban Int J Cardiol 169 2013 e77 e78
2. H. Sun, X. Wang, J.L. Degen, and D. Ginsburg Reduced thrombin generation increases host susceptibility to group A streptococcal infection Blood 113 2009 1358 1364
3. G.S. Chahal, A. Saithna, and M. Brewster et al. A comparison of complications requiring return to theatre in hip and knee arthroplasty patients taking enoxaparin versus rivaroxaban for thromboprophylaxis Ortop Traumatol Rehabil 15 2013 125 129
4. J.H. Alexander, R.D. Lopes, and S. James et al. Apixaban with antiplatelet therapy after acute coronary syndrome N Engl J Med 365 2011 699 708
5. S.J. Connolly, J. Eikelboom, and C. Joyner et al. Apixaban in patients with atrial fibrillation N Engl J Med 364 2011 806 817
6. C.B. Granger, J.H. Alexander, and J.J. McMurray et al. Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 2011 981 992
7. S.J. Connolly, M.D. Ezekowitz, and S. Yusuf et al. Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
8. B.I. Eriksson, O.E. Dahl, and M.H. Huo et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial Thromb Haemost 105 2011 721 729
9. M. Sakon, and M. Nakamura Darexaban (YM150) prevents venous thromboembolism in Japanese patients undergoing major abdominal surgery: Phase III randomized, mechanical prophylaxis-controlled, open-label study Thromb Res 130 2012 e52 e59
10. B.I. Eriksson, L.C. Borris, and R.J. Friedman et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty N Engl J Med 358 2008 2765 2775
11. A.K. Kakkar, B. Brenner, and O.E. Dahl et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial Lancet 372 2008 31 39
12. M.R. Lassen, W. Ageno, and L.C. Borris et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty N Engl J Med 358 2008 2776 2786
13. A.G. Turpie, M.R. Lassen, and B.L. Davidson et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial Lancet 373 2009 1673 1680
14. M.R. Patel, K.W. Mahaffey, and J. Garg et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 2011 883 891
15. EINSTEIN-PE Investigators, H.R. Büller, and M.H. Prins et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism N Engl J Med 366 2012 1287 1297